J. Witter

发表

Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations

David A. Williams, P. Tugwell, R. Freeman, 2016, Pain.

Core outcome measures for chronic pain clinical trials: IMMPACT recommendations

J. Farrar, N. Bellamy, B. Galer, 2003, Pain.

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force

H. Raspe, P. Merkel, P. Bacon, 2007, Annals of the rheumatic diseases.

EULAR recommendations for the management of primary small and medium vessel vasculitis

H. Raspe, P. Merkel, C. Kallenberg, 2008, Annals of the Rheumatic Diseases.

Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations

M. Rowbotham, Z. Bhagwagar, J. Farrar, 2012, PAIN.

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.

David Cella, Charles S Cleeland, Alejandro R Jadad, 2008, The journal of pain : official journal of the American Pain Society.

The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations.

David Borsook, Ralf Baron, Tor D Wager, 2017, The journal of pain : official journal of the American Pain Society.

Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations

Richard E. White, J. Heyse, J. Chandler, 2008, PAIN.

Improving study conduct and data quality in clinical trials of chronic pain treatments: IMMPACT recommendations.

James N. Campbell, M. Rowbotham, R. Freeman, 2019, The journal of pain : official journal of the American Pain Society.

Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges.

David Borsook, Sean Mackey, Jianren Mao, 2013, The journal of pain : official journal of the American Pain Society.

of primary small and medium vessel vasculitis EULAR recommendations for the management

H. Raspe, D. Scott, R. Luqmani, 2009 .

EULAR recommendations for the management of large vessel vasculitis

H. Raspe, P. Merkel, C. Kallenberg, 2008, Annals of the rheumatic diseases.

of large vessel vasculitis EULAR recommendations for the management

H. Raspe, D. Scott, R. Luqmani, 2009 .

What can chronic arthritis pain teach about developing new analgesic drugs?

James Witter, R. Dionne, J. Witter, 2004, Arthritis research & therapy.

NIH-FDA Analgesic Drug Development Workshop: translating scientific advances into improved pain relief.

R. Dionne, J. Witter, 2003, The Clinical journal of pain.

Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials II: the Rheumatology Common Toxicity Criteria v.2.0

P. Brooks, J. Fries, D. Furst, 2007, The Journal of Rheumatology.

Pain and rheumatology: thinking outside the joint.

D. Clauw, J. Witter, 2009, Arthritis and rheumatism.

Drug development in rheumatoid arthritis.

J. Witter, 2002, Current opinion in rheumatology.

Stimulating the development of mechanism-based, individualized pain therapies

J. Woodcock, R. Dionne, J. Witter, 2007, Nature Reviews Drug Discovery.

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations

Richard E. White, J. Farrar, N. Bellamy, 2010, PAIN®.

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis

H. Raspe, P. Merkel, D. Scott, 2006, Annals of the rheumatic diseases.

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations

J. Farrar, N. Bellamy, B. Galer, 2003, Pain.

Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations

Richard E. White, J. Farrar, R. Gershon, 2006, Pain.

Individual responder analyses for pain: does one pain scale fit all?

Jeffrey Mogil, James Witter, L. Bartoshuk, 2005, Trends in pharmacological sciences.

Improving the pharmacologic management of pain in older adults: identifying the research gaps and methods to address them.

D. Bennett, M. C. Reid, J. Hanlon, 2011, Pain medicine.

Rofecoxib, Merck, and the FDA.

J. Witter, Lourdes Villalba, 2004, The New England journal of medicine.

Statement nterpreting the Clinical Importance of Treatment Outcomes n Chronic Pain Clinical Trials : IMMPACT Recommendations

K. Schmader, J. Chandler, J. Farrar, 2008 .

Report of the American College of Rheumatology Pain Management Task Force

R. Altman, D. Pisetsky, L. Crofford, 2010, Arthritis care & research.

OMERACT 7 Workshop Fibromyalgia Syndrome

David A. Williams, L. Arnold, L. Crofford, 2005 .

International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.

G. Serratrice, D. Isenberg, J. Callen, 2004, Rheumatology.

Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations

Richard E. White, J. Farrar, N. Bellamy, 2010, PAIN®.

Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challenges.

J. Zubieta, D. Borsook, S. Mackey, 2013, The journal of pain : official journal of the American Pain Society.

EULAR recommendations for the management of primary small and medium vessel vasculitis

H. Raspe, C. Kallenberg, David Steven Scott, 2008, Annals of the rheumatic diseases.